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ABSTRACT
Background
Only limited research tracks United States trends in the use of statins recorded during
outpatient visits, particularly use by patients at moderate to high cardiovascular risk.
Methods and Findings
Data collected between 1992 and 2002 in two federally administered surveys provided
national estimates of statin use among ambulatory patients, stratified by coronary heart disease
risk based on risk factor counting and clinical diagnoses. Statin use grew from 47% of all lipid-
lowering medications in 1992 to 87% in 2002, with atorvastatin being the leading medication in
2002. Statin use by patients with hyperlipidemia, as recorded by the number of patient visits,
increased significantly from 9% of patient visits in 1992 to 49% in 2000 but then declined to
36% in 2002. Absolute increases in the rate of statin use were greatest for high-risk patients,
from 4% of patient visits in 1992 to 19% in 2002. Use among moderate-risk patients increased
from 2% of patient visits in 1992 to 14% in 1999 but showed no continued growth
subsequently. In 2002, 1 y after the release of the Adult Treatment Panel III recommendations,
treatment gaps in statin use were detected for more than 50% of outpatient visits by
moderate- and high-risk patients with reported hyperlipidemia. Lower statin use was
independently associated with younger patient age, female gender, African American race
(versus non-Hispanic white), and non-cardiologist care.
Conclusion
Despite notable improvements in the past decade, clinical practice fails to institute
recommended statin therapy during many ambulatory visits of patients at moderate-to-high
cardiovascular risk. Innovative approaches are needed to promote appropriate, more
aggressive statin use for eligible patients.
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Coronary heart disease (CHD) remains the leading cause of
morbidity and mortality in the United States and is associated
with substantial economic cost [1]. Hyperlipidemia represents
an important modiﬁable risk factor in the development and
progression of CHD. Estimates indicate that nearly 100
million American adults have total blood cholesterol levels
of greater than 5.17 mmol/l (200 mg/dl) with 40% having
levels greater than 6.21 mmol/l (240 mg/dl) [2]. Identiﬁcation
and treatment of patients with hyperlipidemia play an
essential role in the primary and secondary prevention of
CHD.
Currently, evidence-based practice guidelines focus on low-
density lipoprotein cholesterol (LDL-C) as the primary target
for risk reduction therapy and recommend that the intensity
and target goals of LDL-C-lowering therapy should be
adjusted to individual absolute risk for CHD [3]. Absolute
CHD risk is categorized as low, moderate, or high based on
the presence or absence of CHD, CHD-equivalent conditions,
and major risk factors other than LDL-C. While therapeutic
lifestyle changes are integral to general risk reduction, drug
treatment proves necessary for selected patients whose
absolute risk is high and/or whose LDL-C is inadequately
controlled with lifestyle modiﬁcations alone. Among existing
drug therapies, 3-hydroxy-3-methyl-glutaryl coenzyme A
reductase inhibitors, more commonly known as statins,
provide a generally well-tolerated and effective option for
lowering LDL-C levels and decreasing the likelihood of
subsequent CHD events [3,4].
Despite the compelling evidence of statins’ therapeutic
beneﬁts, the literature abounds with documentation of wide
treatment gaps in clinical practice [5–10]. Available research,
however, offers only a limited understanding of how statin
therapy varies by CHD risk, particularly for statin-eligible
patients in the moderate-risk group. Also, national data are
limited regarding recent changes in statin use.
Using serial cross-sectional data from 1992 through 2002,
we tracked trends in statin use in the United States during
ambulatory visits categorized by CHD risk, with or without a
diagnosis of hyperlipidemia. In addition, we analyzed the
independent associations of patient and physician character-
istics with statin use for insights as to how to target
interventions to improve statin use.
Methods
Data Sources
Annual data from1992 through 2002 were obtained from
the National Ambulatory Medical Care Survey (NAMCS) and
the outpatient department component of the National
Hospital Ambulatory Medical Care Survey (NHAMCS). The
National Center for Health Statistics provides complete
descriptions of both surveys and yearly data at http://
www.cdc.gov/nchs/about/major/ahcd/ahcd1.htm. These sur-
veys, particularly NAMCS, have been validated against other
data sources [11,12], and have also been utilized in past
research of cholesterol management [13].
In brief, NAMCS captures health-care services provided by
ofﬁce-based physicians, while NHAMCS assesses services
offered at hospital outpatient departments. Both surveys
utilize multistage probability sampling procedures, enabling
the generation of nationally representative estimates. Be-
tween 1992 and 2002, annual participation rates among
physicians selected for NAMCS averaged 70%, while the
participation rate in NHAMCS by selected hospitals with
outpatient departments was 90%. In our study, we combined
NAMCS and NHAMCS data to obtain a wider range of
outpatient settings and a broader socioeconomic spectrum of
patients seeking ambulatory care.
Standard encounter forms were completed for a systematic
random sample of patient visits during randomly assigned
reporting periods. Item nonresponse rates were mostly 5% or
less in both surveys for all years. Yearly encounter forms
varied slightly between NAMCS and NHAMCS and were
revised every two years. Our analysis focused on domains of
data that were consistently collected in both NAMCS and
NHAMCS for the time period 1992–2002, including patient
demographic and geography characteristics, reasons for visit
(up to three), diagnoses (up to three), new and continuing
medications (up to ﬁve in 1992–1994 and six in 1995–2002),
and lifestyle counseling services provided or ordered at the
visit.
Participants
CHD risk categorization. We estimated CHD risk for adults
aged 20 y and older based on risk factor counting. CHD risk
was mutually exclusively categorized as low (0–1 risk factors),
moderate (2þ risk factors), or high (CHD, other atheroscler-
otic diseases, or diabetes). The moderate-risk group included
visits by patients without CHD or equivalent but with at least
two of the following risk factors: age (for men, .45 y; for
women, .55 y), cigarette smoking, or a physician-reported
diagnosis of hypertension. Unfortunately, the other two
major CHD risk factors—high-density lipoprotein cholesterol
levels and family history of premature CHD—were not
captured in either data source. Also, neither data source
provided actual cholesterol measurements. Disease condi-
tions were identiﬁed by International Classiﬁcation of
Disease (ICD-9) codes, as well as by the appropriate reason-
for-visit codes that are speciﬁc to NAMCS and NHAMCS. For
instance, we identiﬁed patients as having hyperlipidemia if
their encounter forms contained an International Classiﬁca-
tion of Disease code within 272.0–272.4. For the sake of this
study, patients whose encounter forms did not indicate the
presence of a condition were assumed to not have that
condition.
Patient visit characteristics. Nonclincal characteristics
included patient age, gender, race/ethnicity, medical insur-
ance, visit status, United States census region, metropolitan
area status, physician specialty, and practice setting. Medical
insurance was classiﬁed as private/commercial, public (i.e.,
Medicare and Medicaid), or other (e.g., workers’ compensa-
tion or self-pay). Visit status distinguished ﬁrst-time visits
from return visits to a practice. Physician specialty was
available only from NAMCS, which contributed more than
90% of the total visits for each of the study years. We
categorized physician specialties as cardiology, internal
medicine, general and family practice, or other.
Measures. Of primary interest were the rate of statin use
relative to CHD risk and the relationship of statin use to
patient visit characteristics. The rate of statin use was
calculated as the proportion of patient visits where a statin
was reported (i.e., atorvastatin, lovastatin, pravastatin, sim-
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Statin Use by CHD Riskvastatin, or ﬂuvastatin). Before its removal from the market in
2001, cerivastatin was used scarcely (,2% among visits by
patients with hyperlipidemia) and therefore is not reported
in this study. Measuring the rate of statin use by CHD risk
category provided a relative indicator of appropriate
prescribing patterns, that is, the prevalence of statin use
should be highest among high-risk patients, for whom
secondary prevention is a priority. Variations of statin use
by patient visit characteristics, if detected, would reﬂect a
lack of equity in processes of care in that uniform practices
are expected unless evidence-based guidelines recommend
otherwise.
Analyses. Statistical analyses were performed using SAS for
Windows software (SAS Institute, Cary, North Carolina,
United States) and SAS-callable SUDAAN software (RTI,
Research Triangle Park, North Carolina, United States) to
account for sampling weights and the complex survey design.
The unit of analysis is the patient visit. We report national
annual means of the rate of statin use by CHD risk category
and corresponding 99% conﬁdence intervals for the years
1992 through 2002. v
2 tests examined the association of statin
use with individual patient visit characteristics for combined
1995–2002 NAMCS and NHAMCS data. The independent
effect of each patient visit characteristic on statin use after
controlling for all other characteristics was assessed with
multivariate logistic regression.
Results
In 2002, visits by patients at moderate or high risk involved
higher proportions of older patients (mean age 65 y) than
low-risk patient visits (mean age 51 y), and consequently were
more likely to be covered by public insurance, particularly
Medicaid (Table 1). Moderate- and high-risk patient visits also
were made up of more men and return patients. In addition, a
greater percentage of high-risk patient visits (11%) were seen
by cardiologists than patient visits at low and moderate risk
(2% and 4%, respectively). Internists and general and family
practitioners played a dominant role in the care of moderate-
and high-risk patients, accounting for 69% of visits by
moderate-risk patients and 58% of visits by high-risk patients.
Distributions by race/ethnicity, geographic region, residence
area, and practice setting did not differ by CHD risk. Overall,
the majority of patient visits were return visits to ofﬁce-based
physicians made by non-Hispanic whites and residents living
within metropolitan statistic areas. Patient visits were
distributed similarly across the four geographic regions, with
a slightly higher proportion from the southern region.
Throughout the study period, statins were primarily used
among patients whose visit involved reported hyperlipidemia,
representing 97% of all statin use in 1992 and 91% in 2002.
Statin use increased nearly 5-fold from 9% (99% conﬁdence
interval: 7%–12%) of all visits with reported hyperlipidemia
in 1992 to 49% (42%–55%) in 2000, but then declined to 36%
(31%–42%) in 2002 (Figure 1). Of note, however, the annual
rate of increase in frequency of patient visits with reported
hyperlipidemia was 34% in 2001 and 21% in 2002, while it
averaged only 12% through 2000. The dominance of statins as
lipid-lowering agents grew markedly from 47% of all lipid-
lowering medications in 1992 to 87% in 2002 (Figure 1).
Among available statins, lovastatin remained the therapeutic
Table 1. Differences in Patient, Physician, and Visit Characteristics by CHD Risk in 2002
Characteristic Classification CHD Risk p-Value
Low
a Moderate
a High
a
Age (y) 51 (0.2) 65 (0.4) 65 (0.4) p , 0.0001
Sex (%) Female
Male
66 (0.7)
35 (0.7)
53 (1.4)
47 (1.4)
50 (1.5)
50 (1.5)
p , 0.0001
Race/ethnicity (%) White
African-American
Hispanic
Other
81 (1.1)
9 (0.7)
7 (0.8)
3 (0.5)
78 (3.3)
10 (1.5)
9( 3 . 5 )
3( 0 . 7 )
75 (2.4)
11 (1.3)
9 (2.2)
5 (0.8)
NS
Medical insurance (%) Private
Public
Other
57 (1.2)
28 (1.0)
11 (0.8)
45 (2.4)
46 (2.3)
6( 0 . 9 )
38 (2.1)
54 (2.1)
5 (0.8)
p , 0.0001
Geographic region (%) Northeast
Midwest
South
West
22 (1.7)
22 (2.0)
34 (2.3)
22 (1.4)
31 (2.5)
20 (1.8)
34 (2.9)
15 (1.8)
22 (2.8)
24 (2.8)
34 (3.0)
20 (2.3)
p=0.0002
Residence area (%) Metropolitan Statistic Area (MSA)
Non-MSA
87 (3.1)
13 (3.1)
84 (3.9)
16 (3.9)
82 (4.5)
18 (4.5)
NS
Visit status (%) New
Return
22 (0.8)
78 (0.8)
16 (1.2)
84 (1.2)
16 (1.5)
84 (1.5)
p , 0.0001
Physician specialty (%) Internal Medicine
Cardiology
General/Family Practice
Other
16 (1.5)
2 (0.3)
23 (1.5)
59 (1.6)
40 (2.6)
4( 0 . 6 )
29 (2.0)
27 (1.9)
31 (3.0)
11 (1.6)
27 (2.4)
31 (2.7)
p , 0.0001
Survey type (%) NAMCS
NHAMCS
92 (0.8)
8 (0.8)
93 (1.0)
7( 1 . 0 )
92 (1.2)
8 (1.2)
NS
Sample sizes, with weighted sample sizes in parentheses, are as follows: low-risk group, 40,127 (588,000,000); intermediate-risk group, 4,112 (87,000,000); high-risk group, 4,773 (79,000,000).
a Number in parentheses is standard error.
NS, non-significant.
DOI: 10.1371/journal.pmed.0020123.t001
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Statin Use by CHD Riskchoice through 1996, after which it was surpassed by other
statins, particularly simvastatin and then atorvastatin (Figure
2). Atorvastatin constituted 51% (46%–56%) and simvastatin
32% (27%–36%) of all statin use in 2002.
As expected, high CHD risk patient visits resulted in
greater statin use, and the divergence in statin use among the
three risk categories has grown in recent years. Absolute
increases in the rate of statin use were greatest for high-risk
patient visits with or without reported hyperlipidemia—a 15
percentage-point increase from 4% of all visits in 1992 to
19% in 2002—followed by a nine percentage-point increase
(2% to 11%) for moderate-risk patient visits and a 2.5
percentage-point increase (0.3% to 2.8%) for low-risk patient
visits (Figure 3). Statin use in the moderate-risk group peaked
at 14% (10%–17%) in 1999. Similarly, the rate of statin use in
the high-risk group declined slightly from 2001 to 2002.
Among patient visits with reported hyperlipidemia, statins
were used in 14% (8%–19%) of high-risk visits and 9% (5%–
14%) of moderate-risk visits in 1992. The high-risk group’s
statin use rate rose to 60% (49%–71%) in 2000 and was 50%
(40%–61%) in 2002. Likewise, the rate in the moderate-risk
group climbed to 56% (42%–70%) in 1999 and stabilized at
44% (32%–57%) in 2002. In addition, lifestyle counseling (i.e.,
regarding diet, exercise, or smoking cessation) occurred in
only 43% (32%–53%) of new and general medical examina-
tion visits in 2002 for patients who had moderate CHD risk
and were diagnosed with hyperlipidemia. Improvements over
time in counseling rates were minimal.
The increase in statin use with CHD risk and with the year
of study persisted after controlling for physician-reported
hyperlipidemia, number of medications, and nonclinical
patient visit characteristics (Table 2). Moderate- to high-risk
patient visits had a 1.2- to 2.5-fold greater likelihood of taking
a statin relative to visits by patients at low risk. Statin use was
approximately three times as likely in 2001 and 2002 as in
1995 and 1996. Additionally, lower statin use was independ-
ently associated with younger patient age, female gender,
African American background (versus non-Hispanic white),
non-cardiologist care, and fewer total reported medications.
Discussion
Despite signiﬁcant increases from 1992 to 2002 in use of
statins associated with hyperlipidemic patient visits, the
magnitude of increases is smaller than expected and the rate
of use remains suboptimal according to the best available
evidence. The underuse of statins is most prominent among
visits by patients at high or moderate risk of CHD who do not
have a physician-noted diagnosis of hyperlipidemia but may
nonetheless be eligible for lipid-lowering drug therapy.
Previous research reports that physicians are more likely to
diagnose hyperlipidemia if laboratory reports show abnormal
lipid levels [14]. However, the normal ranges of lipid levels on
many laboratory reports do not take into account individual
patients’ absolute risk.
When evaluating statin use across different CHD risk
categories, the observed trends raise several issues. Both the
rate of statin use and the absolute increases in the rate over
time were positively associated with the level of CHD risk,
which appropriately conforms to the notion of risk strat-
iﬁcation. The associations persisted after adjusting for
potentially confounding factors such as a hyperlipidemia
diagnosis and nonclinical patient visit characteristics. Even
so, in 2002, one year after the publication of Adult Treatment
Panel III [3], statins were reportedly used in only 19% of
patient visits with established CHD or its equivalents, and the
average rate was no higher than 50% among high-risk visits
where a diagnosis of hyperlipidemia also was noted. These
data suggest a dramatic treatment gap. Another analysis
based on national data estimated that 72% of Americans with
existing CHD would beneﬁt from drug therapy to achieve the
target LDL-C goal of 2.59 mmol/l (100 mg/dl) or less, assuming
a 10% LDL-C reduction with diet [15]. However, only 11% of
those eligible individuals received lipid-lowering drug ther-
apy, suggesting a gap of 89% [15]. These obvious treatment
gaps are disconcerting, especially in light of the recent Adult
Treatment Panel III update[16] that supports more intensive
lipid-lowering drug therapy for patients at high and
moderately high risk for a heart attack. Barriers to adequate
treatment of high-risk patients may stem from the patient
Figure 1. Use of Statins and All Lipid-Lowering Medications among
United States Ambulatory Visits by Patients Diagnosed with Hyper-
lipidemia
Data from NAMCS and NHAMCS, 1992–2002.
DOI: 10.1371/journal.pmed.0020123.g001
Figure 2. Share of Total Statin Use among United States Ambulatory
Visits by Individual Statin Medications
Data from NAMCS and NHAMCS, 1992–2002.
DOI: 10.1371/journal.pmed.0020123.g002
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Statin Use by CHD Risk(e.g., lack of drug adherence, concern about adverse effects,
inadequate knowledge of their hyperlipidemia, and drug
cost), the physician (e.g., lack of guideline awareness, failure
to measure lipid levels, and overestimation of actual treat-
ment), and the health-care system (e.g., lack of monitoring
and follow-up and emphasis on acute medical problems) [10].
If the current practice continues, the observed treatment
gaps are expected to persist or even widen.
While statins deliver the greatest beneﬁts when used for
secondary prevention, evidence continues to accumulate that
suggests an important role of statins in the primary
prevention of cardiovascular events, particularly for patients
at increased risk [6,17]. Our data show an increase in statin
use from 2% of moderate-risk patient visits in 1992 to 14% in
1999, but without continued growth subsequently. Optimal
proportions could not be determined because of the lack of
detailed clinical data. Nonetheless, National Health and
Nutrition Examination Survey III data showed that 60% of
38.5 million adult Americans without CHD who had two or
more risk factors had an LDL-C level above the recommen-
ded 3.36 mmol/l (130 mg/dl) and that 45% would remain
eligible for drug therapy even after a 10% decrease in LDL-C
with diet [15]. In addition, Fedder and colleagues found a
doubling effect in the number eligible for primary prevention
drug therapy by switching to Framingham risk scoring [18].
Other researchers have reported that the proportions of
treatment-eligible primary prevention patients who received
no drug therapy reached as high as 97% [5,19]. In our study,
statin use was reported in only 44% of moderate-risk patient
visits for which a diagnosis of hyperlipidemia was noted,
which is surprisingly low given that the entire group would be
expected to beneﬁt from statin therapy. We also concur with
other researchers who have discussed the role that inad-
equate lifestyle counseling plays in the existing cholesterol
treatment gaps [10,13]. Our data show that lifestyle counsel-
ing occurred during fewer than 50% of new and general
medical examination visits by moderate-risk patients, even
though these types of visits arguably represent better
opportunities for counseling services than return, illness-
focused visits.
It is intriguing to note that earlier increases in statin use
were not sustained in 2001 and 2002. Studies using alternative
data sources are needed to corroborate this observation, and
detailed market research is necessary for understanding the
underlying causes of this unexpected decline in use. We
speculate that the observed trends may be partially explained
by discordant rates of increase in the diagnosis of hyper-
lipidemia versus the prescribing of statins. Also, NAMCS and
NHAMCS data released after 2002 will help determine
whether the noted declines are due to random ﬂuctuations
in data reporting.
Wide gaps between evidence-based lipid-lowering therapy
and physician practice were reported in many other western
countries as well. For instance, a survey conducted in nine
European countries found that only 32% of patients with
conﬁrmed CHD received lipid-lowering medications [20].
Likewise, in a population-based study from the Netherlands,
merely 16% of individuals eligible for lipid-lowering drugs
were actually treated [7].
In spite of being clearly underused, statins increasingly
dominate lipid-lowering drug therapy, accounting for 92% of
all lipid-lowering medications used in 2002, which conﬁrms
the trends seen in United States retail pharmacy dispensing
data [2]. Also, in concert with other researchers [21], we
observed a shift in the leading statin prescribed over time,
from lovastatin to simvastatin and then to atorvastatin,
corresponding to their market entry. Atorvastatin accounted
for over half of all statin use in 2002. Even though most
statins share similar tolerability, some evidence shows that
atorvastatin has greater dose-speciﬁc potency for lowering
LDL-C and total cholesterol [22].
Additionally, our data add support to available literature
documenting inequities in use of statins for patients with
different social and clinical characteristics [23–26]. Of
particular note are the lower rates of statin use in at-risk
younger patients, females, African-Americans, and patients
cared for by non-cardiologists. These ﬁndings may be useful
for guiding targeted interventions that aim to bring physician
practice into agreement with published guidelines for
cardiovascular risk reduction.
Our ﬁndings must be interpreted in the context of data
limitations. Although both NAMCS and NHAMCS are
designed to produce nationally representative estimates,
these estimates are not linked to individuals but to patient
visits. As a result, reported statin use may overestimate the
actual administration because patients prescribed drug
therapy likely make more visits because of greater disease
severity and/or the need of frequent follow-ups. Also, we are
missing people with risk factors who have not been seen by a
physician or whose risk factors failed to be recorded. On the
other hand, underestimation is also possible, for example,
because of physicians’ lack of awareness or incomplete
reporting of patient medication uses. However, the failure
to inquire or report an important agent such as a statin may
be a clinical oversight in itself and contribute to therapeutic
gaps. The degree of inaccuracy in our estimates is perhaps
small, however, as suggested by the comparability of the
current results to previous reports.
Lack of detailed clinical data prohibits accurate risk
assessment based on Framingham risk scoring. While the risk
factor counting algorithmt h a tw eu s e dm a ys i m u l a t e
practical risk estimation by many physicians, it precludes
Figure 3. Use of Statins among United States Ambulatory Visits, by CHD
Risk Category
Data from NAMCS and NHAMCS, 1992–2002.
DOI: 10.1371/journal.pmed.0020123.g003
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Statin Use by CHD Riskthe assessment of appropriateness of statin use in relation to
the latest lipid-lowering guidelines. This creates difﬁculty
interpreting the rate of statin use observed for the moderate-
risk group. In particular, adequate information is not
available to differentiate varying levels of absolute risk
among the moderate-risk group. We likely misclassiﬁed some
patients as moderate risk when they may have actually been
high risk despite the absence of CHD or CHD equivalents. On
the other hand, indications for statins might be marginal for
some young patients with modestly elevated risk factors. A
ﬁnal caveat is that neither NAMCS nor NHAMCS captures
patient compliance or outcomes, although these are perhaps
separate issues from physician adherence to evidence-based
medicine.
Despite the acknowledged limitations, NAMCS and
NHAMCS cover a longer consecutive time span and provide
more complete information about disease-speciﬁc physician
activities than many other national data bases, e.g., the
Medical Expenditures Panel Survey, the National Health
Assessment Nutrition Examination Survey, and the National
Health Interview Survey.
In conclusion, persistent gaps in statin therapy suggest a
continued need for improved CHD risk stratiﬁcation of all
patients, and treatment with statins when indicated. Infor-
mation technology and broader national policy around
quality measurement and reporting are just two potential
strategies that could be used to improve current practice.
Patient-centered interventions should strengthen patient
education and improve patient access to different treatment
options. Interventions should be targeted to at-risk patients
whose drug regimens need to be reassessed and to physicians,
particularly non-cardiologists, whose practices need be
improved. Guidelines for cardiovascular risk reduction treat-
ment and determination of the speciﬁc patients who can
beneﬁt from statin therapy will continue to evolve. Indica-
tions for use in primary CHD prevention are likely to expand
for statins. Given the observed practice shortfalls, drug
therapy in moderate-risk patients remains an important
priority for improvement.
Table 2. Predictors of Statin Use with Combined 1995–2002 NAMCS and NHAMCS Data
Characteristic Classification Statin Use (%)
a Adjusted Odds Ratios
b,c
CHD risk Low
Moderate
High
2.0 (0.1)
8.2 (0.4)
15.0 (0.5)
1.00 (reference)
1.24 (0.97–1.59)
2.47 (1.99–3.06)
Hyperlipidemia No
Yes
2.6 (0.1)
41.4 (1.2)
1.00 (reference)
36.84 (26.06–52.08)
Age group (y) 20–44
45–64
65–79
.80
0.7 (0.1)
4.9 (0.2)
7.4 (0.3)
4.6 (0.3)
1.00 (reference)
2.96 (2.30–3.80)
3.42 (2.53–4.63)
1.88 (1.31–2.71)
Sex (%) Male
Female
5.3 (0.2)
3.1 (0.1)
1.00 (reference)
0.60 (0.52–0.70)
Race/ethnicity (%) White
African-American
Hispanic
Other
3.9 (0.1)
3.0 (0.3)
2.6 (0.3)
3.2 (0.6)
1.00 (reference)
0.77 (0.61–0.98)
0.83 (0.63–1.08)
0.90 (0.60–1.35)
Medical insurance (%) Private
Public
Other
3.4 (0.1)
6.0 (0.2)
1.8 (0.1)
1.00 (reference)
0.85 (0.70–1.03)
0.82 (0.65–1.04)
Residence area (%) Metropolitan Statistic Area (MSA)
Non-MSA
3.8 (0.1)
4.5 (0.4)
1.13 (0.92–1.39)
1.00 (reference)
Geographic region (%) Northeast
Midwest
South
West
4.6 (0.3)
4.4 (0.2)
3.6 (0.2)
3.3 (0.2)
1.29 (0.96–1.74)
1.18 (0.88–1.57)
1.05 (0.79–1.39)
1.00 (reference)
Visit status (%) New
Return
3.4 (0.2)
4.1(0.1)
1.12 (0.94–1.34)
1.00 (reference)
Physician specialty (%) Cardiology
Internal Medicine
General/Family Practice
Other
19.7 (1.1)
7.5 (0.5)
4.3 (0.2)
1.5 (0.1)
1.00 (reference)
0.56 (0.43–0.74)
0.46 (0.36–0.58)
0.33 (0.25–0.44)
Survey year 1995–1996
1997–1998
1999–2000
2001–2002
1.9 (0.1)
3.1 (0.2)
4.8 (0.2)
5.5 (0.3)
1.00 (reference)
1.64 (1.25–2.14)
2.36 (1.90–2.92)
2.65 (2.07–3.39)
Survey type (%) NAMCS
NHAMCS
4.0 (0.1)
3.4 (0.2)
0.85 (0.66–1.09)
Number of medications — 1.70 (1.63–1.76)
a Numbers in parentheses are standard errors.
b The odds ratio for each variable was adjusted for all other variables listed in the table.
c Numbers in parentheses are 99% confidence intervals.
DOI: 10.1371/journal.pmed.0020123.t002
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Patient Summary
Background Statins, a group of drugs that block a part of the pathway
essential in forming lipids, have been shown to be very effective in
reducing the chances of heart attacks and stroke both in people who
have already had such an illness, and also in otherwise healthy people
who have multiple risk factors. Long-term data are limited regarding
whether people who might most benefit from such drugs are in fact
receiving them.
What Did the Investigators Do? Using two large United States
outpatient care surveys that have run for many years, they looked at
information on how doctors prescribed these drugs to patients. They
found that between 1992 and 2002 the proportion of visits by patients
with high lipid levels during which statins were prescribed rose from 9%
in 1992 to 49% in 2000 and then fell to 36%. By 2002, statins were the
dominant drug used for people with high lipid levels, accounting for
87% of all prescribed lipid-lowering medications. Although people at
highest risk of cardiovascular diseases (with or without high lipid levels)
were most likely to be prescribed a statin, by 2002, statins were
prescribed in only 19% of visits by these people. In addition, only 11% of
visits by people with multiple risk factors received a statin. Less than half
the patient visits that arguably represent optimal opportunities for
counseling services received counseling about how they might improve
their cardiovascular health through lifestyle changes. Other factors that
led to lower prescribing of statins were younger patient age, female
gender, African American background, and care by non-cardiologists.
What Do These Findings Mean? It seems that many people who could
benefit from statins are not receiving them. Equally importantly, many
people also did not receive information about how they could modify
their lifestyle.
Where Can I Get More Information? MedlinePlus has information on
high lipids: go to http://www.nlm.nih.gov/medlineplus and search for
‘‘hyperlipidemia’’
The British Heart Foundation has a number of pages on lipids: go to
http://www.bhf.org.uk and search for ‘‘lipids’’
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